Analyzing Cue Health (NASDAQ:HLTH) and EyePoint Pharmaceuticals (NASDAQ:EYPT)

Cue Health (NASDAQ:HLTHGet Rating) and EyePoint Pharmaceuticals (NASDAQ:EYPTGet Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Cue Health and EyePoint Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Health 0 0 0 0 N/A
EyePoint Pharmaceuticals 0 0 3 0 3.00

EyePoint Pharmaceuticals has a consensus target price of $29.50, indicating a potential upside of 161.06%. Given EyePoint Pharmaceuticals’ higher possible upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than Cue Health.

Insider & Institutional Ownership

26.4% of Cue Health shares are owned by institutional investors. Comparatively, 87.7% of EyePoint Pharmaceuticals shares are owned by institutional investors. 26.7% of EyePoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares Cue Health and EyePoint Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cue Health N/A N/A N/A
EyePoint Pharmaceuticals -159.70% -46.76% -29.30%

Valuation & Earnings

This table compares Cue Health and EyePoint Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cue Health $618.11 million 1.59 $86.42 million N/A N/A
EyePoint Pharmaceuticals $35.31 million 10.89 -$58.42 million ($2.02) -5.59

Cue Health has higher revenue and earnings than EyePoint Pharmaceuticals.

About Cue Health (Get Rating)

Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors. It also provides COVID-19 testing kits for the Cue Health Monitoring System The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.

About EyePoint Pharmaceuticals (Get Rating)

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Receive News & Ratings for Cue Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Health and related companies with's FREE daily email newsletter.